Pharma 25 2020 report

Brand Finance Pharma 25 2020

  • Johnson & Johnson leads as industry’s most valuable brand in Brand Finance Pharma 25 2020 ranking, despite 11% drop in brand value to US$10.9 billion 
  • Sector’s strongest brand Roche distances Swiss rival Novartis
  • Bayer drops 17% as brand image tainted by Monsanto acquisition 
  • Pfizer is sector’s fastest-falling brand this year, down 20%
  • Sinopharm & Takeda impressive new entrants from Asia, as ranking extended to encompass sector’s 25 most valuable brands for first time

Johnson & Johnson is the most valuable pharma brand thanks to its continued investment in research and development, most recently in a vaccine designed to battle the deadly coronavirus. With a timely and relevant R&D programme, Johnson & Johnson can hope to maintain its prime position in the industry for years to come.

Richard Haigh Managing Director, Brand Finance

Read about this and many more insights in the full report, available for download now.